NASDAQ$OMCL
Omnicell Inc. · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported record bookings, revenues, and non-GAAP EBITDA, supported by customer demand.
Omnicell reported a 25% increase in GAAP revenues for Q4 2021, reaching $311.0 million, driven by strong demand for medication management and adherence automation solutions, as well as contributions from the acquisition of RxInnovation Inc., operating as FDS Amplicare. GAAP net income for the quarter was $14.0 million, or $0.28 per diluted share. The company achieved record bookings, revenues, and non-GAAP EBITDA in 2021.
- Total GAAP revenues for the fourth quarter of 2021 were $311.0 million, up 25% from the fourth quarter of 2020.
- GAAP net income for the fourth quarter 2021 was $14.0 million, or $0.28 per diluted share.
- Total non-GAAP revenues for the fourth quarter of 2021 were $311.7 million, up 25% from the fourth quarter of 2020.
- Non-GAAP net income for the fourth quarter of 2021 was $43.5 million, or $0.92 per diluted share.
Headline financials
Revenue & EPS history
Omnicell · Revenue · Quarterly
$311M
Revenue by segment
Omnicell · $224M total across 1 segment · Q4 2021
- Product revenues$224M+27.2%100.0%
Forward guidance
For the full year 2022, the Company expects total GAAP and non-GAAP revenues to be between $1.385 billion and $1.410 billion. For the first quarter of 2022, the Company expects total GAAP and non-GAAP revenues to be between $312 million and $318 million.
Tailwinds
- Full year 2022 product bookings to be between $1.370 billion and $1.430 billion.
- Full year 2022 total GAAP and non-GAAP revenues to be between $1.385 billion and $1.410 billion.
- Full year 2022 GAAP and non-GAAP product revenues to be between $950 million and $965 million.
- Full year 2022 GAAP and non-GAAP service revenues to be between $435 million and $445 million.
- Full year 2022 non-GAAP EBITDA to be between $243 million and $255 million.
Headwinds
- First quarter 2022 total GAAP and non-GAAP revenues to be between $312 million and $318 million.
- First quarter 2022 GAAP and non-GAAP product revenues to be between $216 million and $219 million.
- First quarter 2022 GAAP and non-GAAP service revenues to be between $96 million and $99 million.
- First quarter 2022 non-GAAP EBITDA to be between $45 million and $49 million.
- First quarter 2022 non-GAAP earnings to be between $0.65 and $0.72 per share.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+0.7%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+4.7%
Avg return
30 days after
55%
36 / 65 earnings
Positive
+34.3%
Q2 2024
Best reaction
-29.4%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.2% | +13.7% | +18.8% | |
| Q4 2025 | -16.3% | -16.5% | -11.5% | |
| Q3 2025 | +13.4% | +16.7% | +23.5% | |
| Q1 2025 | -16.0% | -15.4% | +1.2% | |
| Q4 2024 | -11.2% | -7.1% | -16.7% | |
| Q3 2024 | +21.2% | +20.9% | +16.1% | |
| Q2 2024 | +34.3% | +41.6% | +52.3% | |
| Q1 2024 | +10.9% | +11.5% | +19.9% | |
| Q4 2023 | -15.6% | -11.9% | -12.0% | |
| Q3 2023 | -14.9% | -13.9% | -5.5% | |
| Q2 2023 | +2.3% | +2.9% | -10.0% | |
| Q1 2023 | +8.9% | +7.1% | +18.6% | |
| Q4 2022 | +7.9% | +6.6% | +6.4% | |
| Q3 2022 | -29.4% | -35.9% | -33.4% | |
| Q2 2022 | -2.1% | -5.6% | -10.6% | |
| Q1 2022 | +1.2% | +5.9% | +4.7% | |
| Q4 2021 | -9.6% | -18.4% | -11.5% | |
| Q3 2021 | +2.2% | +1.6% | +1.5% | |
| Q2 2021 | -1.1% | +0.4% | +7.1% | |
| Q1 2021 | +1.8% | -1.5% | -2.4% | |
| Q4 2020 | +7.0% | +8.9% | +6.5% | |
| Q3 2020 | +2.3% | +2.9% | +27.0% | |
| Q2 2020 | +9.1% | +5.5% | +2.7% | |
| Q1 2020 | -6.1% | -12.3% | -0.5% | |
| Q4 2019 | -1.4% | +2.3% | -4.5% | |
| Q3 2019 | -3.7% | -1.9% | +7.4% | |
| Q2 2019 | +6.7% | +5.4% | +0.6% | |
| Q1 2019 | +0.7% | +3.8% | +4.7% | |
| Q4 2018 | +17.9% | +21.0% | +28.0% | |
| Q3 2018 | +6.1% | +15.2% | +18.8% | |
| Q2 2018 | +13.7% | +13.0% | +29.5% | |
| Q1 2018 | +1.6% | -0.1% | +5.3% | |
| Q4 2017 | -6.2% | -9.8% | -12.9% | |
| Q3 2017 | -6.4% | -8.2% | -7.6% | |
| Q2 2017 | +12.5% | +16.3% | +12.1% | |
| Q1 2017 | -3.2% | -1.7% | +0.0% | |
| Q4 2016 | -0.7% | +1.0% | +4.5% | |
| Q3 2016 | -6.3% | -6.8% | +3.2% | |
| Q2 2016 | +6.8% | +4.7% | +3.4% | |
| Q1 2016 | +3.9% | — | — | |
| Q4 2015 | -1.0% | — | — | |
| Q3 2015 | -10.5% | — | — | |
| Q2 2015 | -8.8% | — | — | |
| Q1 2015 | -2.6% | — | — | |
| Q4 2014 | +5.3% | — | — | |
| Q3 2014 | +9.7% | — | — | |
| Q2 2014 | -3.9% | — | — | |
| Q1 2014 | +0.4% | — | — | |
| Q4 2013 | +8.9% | — | — | |
| Q3 2013 | -1.4% | — | — | |
| Q2 2013 | +8.7% | — | — | |
| Q1 2013 | +7.6% | — | — | |
| Q3 2010 | -1.3% | — | — | |
| Q4 2012 | +13.4% | — | — | |
| Q3 2012 | +12.2% | — | — | |
| Q2 2012 | +0.9% | — | — | |
| Q1 2011 | -0.3% | — | — | |
| Q1 2012 | +4.8% | — | — | |
| Q4 2011 | +2.6% | — | — | |
| Q4 2009 | +2.6% | — | — | |
| Q3 2011 | -0.7% | — | — | |
| Q2 2010 | -16.9% | — | — | |
| Q2 2011 | -16.9% | — | — | |
| Q4 2010 | -16.9% | — | — | |
| Q1 2010 | +7.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro